Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Cecile Leyronnas"'
Autor:
Murielle Roussel, Peter Mollee, Antoine Huart, Hasib Sidiqi, Noemi Horvath, Lionel Karlin, Caroline Jacquet, Pierre Morel, Cecile Leyronnas, Sebastien Bender, Frank Bridoux, Arnaud Jaccard, Simon D. Gibbs
Publikováno v:
Blood. 140:12618-12620
Autor:
Sophie Park, Olivier Kosmider, Frédéric Maloisel, Bernard Drenou, Nicolas Chapuis, Thibaud Lefebvre, Zoubida Karim, Hervé Puy, Anne Sophie Alary, Sarah Ducamp, Frédérique Verdier, Cécile Bouilloux, Alice Rousseau, Marie-Christine Jacob, Agathe Debliquis, Agnes Charpentier, Emmanuel Gyan, Bruno Anglaret, Cecile Leyronnas, Selim Corm, Borhane Slama, Stephane Cheze, Kamel Laribi, Shanti Amé, Christian Rose, Florence Lachenal, Andrea Toma, Gian Matteo Pica, Martin Carre, Frédéric Garban, Clara Mariette, Jean-Yves Cahn, Mathieu Meunier, Olivier Herault, Pierre Fenaux, Orianne Wagner-Ballon, Valerie Bardet, Francois Dreyfus, Michaela Fontenay
Publikováno v:
Haematologica, Vol 104, Iss 3 (2019)
Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in patients with lower-risk myelodysplastic syndrome. We prospectively investigated the predictive value of somatic mutations, and biomarkers of ineffective erythro
Externí odkaz:
https://doaj.org/article/d465efe30d0a4795a3a8445ef181d7b6
Autor:
Adrien Daniel, Samuel Ng, Liam Hackett, Cécile Tomowiak, Christoph Kornauth, Jehan Dupuis, Loïc Renaud, Charles Herbaux, Cédric Rossi, Mary C Collins, Kamel Laribi, Rebecca Valentin, Jean Valère Malfuson, Stéphanie Poulain, Olivier Tournilhac, Fatiha Merabet, Mourad Tiab, Stephen Jun Fei Chong, Philipp B. Staber, Eric Van Den Neste, Loic Ysebaert, Damien Roos-Weil, Matthew S. Davids, Cecile Leyronnas, Franck Morschhauser, François Lemonnier
Publikováno v:
Blood
Blood, American Society of Hematology, 2021, 137 (25), pp.3495-3506. ⟨10.1182/blood.2020007303⟩
Blood, Vol. 137, no.25, p. 3495-3506 (2021)
Blood, American Society of Hematology, 2021, 137 (25), pp.3495-3506. ⟨10.1182/blood.2020007303⟩
Blood, Vol. 137, no.25, p. 3495-3506 (2021)
Conventional therapies for patients with T-cell prolymphocytic leukemia (T-PLL), such as cytotoxic chemotherapy and alemtuzumab, have limited efficacy and considerable toxicity. Several novel agent classes have demonstrated preclinical activity in T-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::968112cbc670b16605d309633d008069
https://hal.uca.fr/hal-03440992
https://hal.uca.fr/hal-03440992
Autor:
Brigitte Pegourie, Frédérique Orsini-Piocelle, Charles Zarnitsky, Benoit Bareau, Jean-Gabriel Fuzibet, Eric Voog, Philippe Rodon, Sophie Auger-Quittet, Xavier Leleu, Olivier Decaux, Eileen M Boyle, Bohrane Slama, Lotfi Benboubker, Gilles Pernod, Philippe Rey, Bruno Royer, Lionel Karlin, Cecile Leyronnas, Karim Belhadj-Merzoug, Manuel Cliquennois, Mourad Tiab, J.-L. Bosson
Publikováno v:
American Journal of Hematology. 94:635-640
The risk of venous thromboembolism (VTE) is higher in myeloma patients receiving immunomodulatory compounds. A VTE prophylaxis using low-molecular-weight heparin or aspirin is therefore proposed. Apixaban is an oral direct anti-Xa. Several studies ha
Autor:
Anouk Emadali, Clémence Deteix-Santana, Emmanuel Bachy, Christine Lefebvre, Séverine Valmary-Degano, Justine Cristante, Cecile Leyronnas, Béatrice Grange, Bruno Tesson, Sophie Dupire, Sylvain Carras, Simon Chevalier, Gilles Salles, Frédérique Orsini-Piocelle, Lucile Bussot, Sarah Huet, Remy Gressin
Publikováno v:
British journal of haematologyReferences. 194(2)
Follicular lymphomas (FLs) with MYC rearrangements (MYC-R) and extra copies of MYC (MYC-EC) are rare and the prognosis impact is uncertain. We conducted a retrospective study including 321 FL patients, among whom 259 (81%) had no 8q24 alterations and
Autor:
Hervé Puy, Pierre Fenaux, Jean-Yves Cahn, Frédérique Verdier, Clara Mariette, Agathe Debliquis, Anne Sophie Alary, Florence Lachenal, Cecile Leyronnas, Olivier Herault, Orianne Wagner-Ballon, Shanti Ame, Zoubida Karim, Alice Rousseau, Bernard Drenou, Agnès Charpentier, Martin Carre, François Dreyfus, Stéphane Cheze, Frédéric Maloisel, Olivier Kosmider, Thibaud Lefebvre, Cécile Bouilloux, F Garban, Sarah Ducamp, Mathieu Meunier, Michaela Fontenay, Borhane Slama, Sophie Park, Andrea Toma, Marie-Christine Jacob, Christian Rose, Kamel Laribi, Selim Corm, Emmanuel Gyan, Valérie Bardet, Bruno Anglaret, Nicolas Chapuis, Gian Matteo Pica
Publikováno v:
Haematologica
Haematologica, 2019, 104 (3), pp.497-504. ⟨10.3324/haematol.2018.203158⟩
Haematologica, Ferrata Storti Foundation, 2019, 104 (3), pp.497-504. ⟨10.3324/haematol.2018.203158⟩
Haematologica, 2019, 104 (3), pp.497-504. ⟨10.3324/haematol.2018.203158⟩
Haematologica, Ferrata Storti Foundation, 2019, 104 (3), pp.497-504. ⟨10.3324/haematol.2018.203158⟩
International audience; Erythropoiesis-stimulating agents are generally the first line of treatment of anemia in patients with lower-risk myelodysplastic syndrome. We prospectively investigated the predictive value of somatic mutations, and biomarker
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f287510a403b2a3876a6f8f51819839a
https://hal.science/hal-02351432/file/1040497.pdf
https://hal.science/hal-02351432/file/1040497.pdf
Autor:
Jean Valère Malfuson, Mourad Tiab, Mary C Collins, Nicolas Vanlangendonck, Rebecca Valentin, Jehan Dupuis, Matthew S. Davids, Samuel Ng, Christoph Kornauth, Adrien Daniel, Kamel Laribi, Stéphanie Poulain, Charles Herbaux, Philipp B. Staber, Olivier Tournilhac, Fatiha Merabet, Micha Srour, Cédric Rossi, Cécile Tomowiak, Franck Morschhauser, Stephen Jun Fei Chong, Damien Roos-Weil, Cecile Leyronnas
Publikováno v:
61st Annual Meeting and Exposition of the American Society of Hematology
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. pp.807
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. pp.807
Introduction: Response to conventional therapies for patients with T-cell prolymphocytic leukemia (T-PLL) is usually poor and is associated with short survival. The BCL-2 antagonist venetoclax was recently found to have some clinical activity in this
Autor:
Kamel Laribi, Stéphane Cheze, Selim Corm, Frédéric Garban, Jean-Yves Cahn, Emmanuel Gyan, Valérie Bardet, Marie-Christine Jacob, Michaela Fontenay, François Dreyfus, Nicolas Chapuis, Zoubida Karim, Bruno Anglaret, Martin Carre, Thibaud Lefebvre, Mathieu Meunier, Olivier Herault, Sophie Park, Andrea Toma, Borhane Slama, Clara Mariette, Bernard Drenou, Agnès Charpentier, Shanti Ame, Christian Rose, Frédérique Verdier, Sarah Ducamp, Alice Rousseau, Agathe Debliquis, Cecile Bouilloux, Olivier Kosmider, Hervé Puy, Orianne Wagner-Ballon, Pierre Fenaux, Anne Sophie Alary, Florence Lachenal, Cecile Leyronnas, Frédéric Maloisel, Gian Matteo Pica
Publikováno v:
SSRN Electronic Journal.
INTRODUCTION: Erythropoiesis stimulating agents (ESA) are generally the first line of treatment of anaemia in lower risk myelodysplastic syndrome (MDS) patients. We prospectively investigated the predictive value of somatic mutations, and biomarkers
Autor:
Pegourie, Brigitte, Karlin, Lionel, Benboubker, Lotfi, Orsini‐Piocelle, Frédérique, Tiab, Mourad, Auger‐Quittet, Sophie, Rodon, Philippe, Royer, Bruno, Leleu, Xavier, Bareau, Benoit, Cliquennois, Manuel, Fuzibet, Jean‐Gabriel, Voog, Eric, Belhadj‐Merzoug, Karim, Decaux, Olivier, Rey, Philippe, Slama, Bohrane, Leyronnas, Cecile, Zarnitsky, Charles, Boyle, Eileen
Publikováno v:
American Journal of Hematology; Jun2019, Vol. 94 Issue 6, p635-640, 6p
Publikováno v:
Genomics & Genetics Weekly; 2/17/2023, p469-469, 1p